- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Marcus Snow: Automatic Substitution of Biosimilars in Rheumatology
Marcus H. Snow, MD, Assistant Professor Rheumatology, University of Nebraska, discusses concerns about automatic substitution of biosimilars for reference products.
Transcript:
Do you have concerns about automatic substitution of biosimilars for reference products?
Yes, I do and I guess I don’t, to some degree. I do have [concerns with] automatic substitution, but it depends on who is doing the substitution and what is being substituted. If I place someone on a new medication and instead of getting the bio-originator product, I get a biosimilar as my first medication, right now I have no qualms about that. The patient is starting on a new medication, it is what it is, and we will see how they respond. However, if they are already on a bio-originator product and they are switched over, I have some concerns about switching a patient who is doing well. The third avenue where you could see switching, which I would be very opposed to, would be someone who is on medication—we’ll say etanercept—and the insurance company or the payer decides that adalimumab biosimilar is the medication of choice. Switching a patient from one drug, not only to a biosimilar, but to a biosimilar of another medication, has huge implications and is very concerning for me. As a rheumatologist, the problem with rheumatoid arthritis is that early on, we have joint damage, and if you lose control of the disease activity, in the long run you can see worse outcomes with increasing rates of disability, etc.
Comparable Disease Activity, Drug Persistence in Patients With JIA Who Switch to Biosimilars
September 12th 2024Switching children with juvenile idiopathic arthritis (JIA) from anti-tumor necrosis factor (TNF) originators to biosimilars showed similar disease activity and drug persistence, with good tolerability, supporting the safety and effectiveness of non-medical switching.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Prioritizing Patient-Centered Care in PsA: Key Insights From the 2023 EULAR Guidelines
August 29th 2024The 2023 European Alliance of Associations for Rheumatology (EULAR) recommendations for psoriatic arthritis (PsA) provide an evidence-based treatment strategy, prioritizing conventional and biological disease-modifying antirheumatic drugs, including biosimilars, tailored to disease manifestations, with an emphasis on safety, cost-effectiveness, and patient-centered care.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
August 19th 2024CMS announced negotiated prices for 10 drugs under the Inflation Reduction Act (IRA), sparking mixed reactions, with concerns that including drugs facing imminent biosimilar competition could hinder market access to lower-cost alternatives.
No Differences in Long-Term Drug Survival Between Biosimilar, Originator TNF Inhibitors
August 15th 2024An analysis of subcutaneous biosimilar and originator tumor necrosis factor (TNF) inhibitors for rheumatic diseases found no significant differences in survival or discontinuation rates due to inefficacy or adverse events, with biosimilars showing lower overall discontinuation rates and higher retention rates.
